Paper8324745
Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics.
Hinman LM and 5 others. Cancer Res, 1993. Cited by 187 papers, by iCite.
Cite this record
ConductScience Library. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Papers, record 8324745. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8324745
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Bacterial Agents | Major topic |
| Antibiotics, Antineoplastic | Major topic |
| Aminoglycosides | |
| Animals | |
| Antibodies, Monoclonal | |
| Breast Neoplasms | |
| Drug Screening Assays, Antitumor | |
| Feasibility Studies | |
| Female | |
| Humans | |
| Leukemia P388 | |
| Mice | |
| Mice, Nude | |
| Molecular Structure | |
| Structure-Activity Relationship | |
| Tumor Cells, Cultured |
Source PubMed
Cited by56
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 187 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42747695 | Outcomes by Body Mass Index in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin. | Target Oncol | 2026 | https://conductscience.org/library/papers/42747695 | PubMed |
| 41184856 | Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions. | Mol Cancer | 2025 | https://conductscience.org/library/papers/41184856 | PubMed |
| 39568595 | Technical, preclinical, and clinical developments of Fc-glycan-specific antibody-drug conjugates. | RSC Med Chem | 2025 | https://conductscience.org/library/papers/39568595 | PubMed |
| 39201338 | Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to Nature-Inspired Payloads. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39201338 | PubMed |
| 38665947 | Antibody-drug conjugates in urothelial carcinoma: scientometric analysis and clinical trials analysis. | Front Oncol | 2024 | https://conductscience.org/library/papers/38665947 | PubMed |
| 37336296 | Modulating antibody effector functions by Fc glycoengineering. | Biotechnol Adv | 2023 | https://conductscience.org/library/papers/37336296 | PubMed |
| 35646299 | Relapsed acute lymphoblastic leukaemia after allogeneic stem cell transplantation: a therapeutic dilemma challenging the armamentarium of immunotherapies currently available (case reports). | Ther Adv Hematol | 2022 | https://conductscience.org/library/papers/35646299 | PubMed |
| 35318309 | Antibody drug conjugate: the "biological missile" for targeted cancer therapy. | Signal Transduct Target Ther | 2022 | https://conductscience.org/library/papers/35318309 | PubMed |
| 34944865 | Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34944865 | PubMed |
| 34641391 | An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy. | Molecules | 2021 | https://conductscience.org/library/papers/34641391 | PubMed |
| 34155147 | Uncialamycin-based antibody-drug conjugates: Unique enediyne ADCs exhibiting bystander killing effect. | Proc Natl Acad Sci U S A | 2021 | https://conductscience.org/library/papers/34155147 | PubMed |
| 32319494 | Perspectives from nearly five decades of total synthesis of natural products and their analogues for biology and medicine. | Nat Prod Rep | 2020 | https://conductscience.org/library/papers/32319494 | PubMed |
| 31816964 | Antibody Structure and Function: The Basis for Engineering Therapeutics. | Antibodies (Basel) | 2019 | https://conductscience.org/library/papers/31816964 | PubMed |
| 31643051 | Click Chemistry Conjugations. | Methods Mol Biol | 2020 | https://conductscience.org/library/papers/31643051 | PubMed |
| 31360093 | Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia. | Blood Lymphat Cancer | 2018 | https://conductscience.org/library/papers/31360093 | PubMed |
| 31104399 | MALDI-MS: a Rapid and Reliable Method for Drug-to-Antibody Ratio Determination of Antibody-Drug Conjugates | Iran Biomed J | 2019 | https://conductscience.org/library/papers/31104399 | PubMed |
| 30898889 | The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia. | Oncologist | 2019 | https://conductscience.org/library/papers/30898889 | PubMed |
| 30093401 | Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group. | Haematologica | 2019 | https://conductscience.org/library/papers/30093401 | PubMed |
| 30087554 | Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. | Drug Des Devel Ther | 2018 | https://conductscience.org/library/papers/30087554 | PubMed |
| 29296758 | Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. | Blood Adv | 2017 | https://conductscience.org/library/papers/29296758 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8324745
GET https://conductscience.org/api/papers/v1/8324745/cited_by?page=2